多発性骨髄腫における従来型化学療法薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

• 英文タイトル：Global Traditional Chemotherapy Drugs for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024

• レポートコード：B-GIR08C5861
• 出版社/出版日：GlobalInfoResearch / 2019年8月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、138ページ
• 納品方法：Eメール
• 産業分類：Pharma & Healthcare

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

本調査レポートは、多発性骨髄腫における従来型化学療法薬の世界市場について調べ、まとめました。種類別セグメントは、メルファラン、ビンクリスチン、シクロホスファミド、エトポシド、ドキソルビシン、リポソームドキソルビシン、ベンダムスチン、その他等、用途別セグメントは、コンシューマー事業、エンタープライズ事業、オペレーター事業等に区分しました。多発性骨髄腫における従来型化学療法薬の世界市場概観、企業動向、企業別多発性骨髄腫における従来型化学療法薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。
・多発性骨髄腫における従来型化学療法薬の市場概観
・多発性骨髄腫における従来型化学療法薬の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等）
・多発性骨髄腫における従来型化学療法薬の企業別販売動向、市場シェア、市場集中度、競争動向
・多発性骨髄腫における従来型化学療法薬の世界市場規模
・多発性骨髄腫における従来型化学療法薬の北米市場分析（アメリカ、カナダ、メキシコ等）
・多発性骨髄腫における従来型化学療法薬のアメリカ市場規模推移
・多発性骨髄腫における従来型化学療法薬のカナダ市場規模推移
・多発性骨髄腫における従来型化学療法薬のメキシコ市場規模推移
・多発性骨髄腫における従来型化学療法薬のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等）
・多発性骨髄腫における従来型化学療法薬のドイツ市場規模推移
・多発性骨髄腫における従来型化学療法薬のイギリス市場規模推移
・多発性骨髄腫における従来型化学療法薬のロシア市場規模推移
・多発性骨髄腫における従来型化学療法薬のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等）
・多発性骨髄腫における従来型化学療法薬の日本市場規模推移
・多発性骨髄腫における従来型化学療法薬の中国市場規模推移
・多発性骨髄腫における従来型化学療法薬の韓国市場規模推移
・多発性骨髄腫における従来型化学療法薬のインド市場規模推移
・多発性骨髄腫における従来型化学療法薬の東南アジア市場規模推移
・多発性骨髄腫における従来型化学療法薬の南米市場分析（ブラジル、アルゼンチン等）
・多発性骨髄腫における従来型化学療法薬の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等）
・多発性骨髄腫における従来型化学療法薬の種類別分析/販売量、売上、市場シェア（メルファラン、ビンクリスチン、シクロホスファミド、エトポシド、ドキソルビシン、リポソームドキソルビシン、ベンダムスチン、その他）
・多発性骨髄腫における従来型化学療法薬の用途別分析/市場規模（コンシューマー事業、エンタープライズ事業、オペレーター事業）
・多発性骨髄腫における従来型化学療法薬の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測）
・多発性骨髄腫における従来型化学療法薬の販売チャネル・代理店・貿易業者・ディーラー分析

Scope of the Report:
The global Traditional Chemotherapy Drugs for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Traditional Chemotherapy Drugs for Multiple Myeloma.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Traditional Chemotherapy Drugs for Multiple Myeloma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Traditional Chemotherapy Drugs for Multiple Myeloma market by product type and applications/end industries.

Market Segment by Companies, this report covers
GlaxoSmithKline
Celon Laboratories
Natco Pharma
Emcure Pharmaceuticals
GLS Pharma
Talon Therapeutics
Shenzhen Main Luck Pharmaceuticals
Cipla
ACTIZA
Hospira
Baxter
Roxane
Sanofi
CSC Pharmaceuticals
LGM Pharma
Pfizer
Merck
Allergan
Teva
Mylan
Qilu Pharmaceutical
Sun Pharmaceuticals
Cadila Pharmaceuticals
Simcere Pharmaceutical
Get Well Pharmaceutical

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Melphalan
Vincristine
Cyclophosphamide
Etoposide
Doxorubicin
Liposome Doxorubicin
Bendamustine
Other

Market Segment by Applications, can be divided into
Hospital
Clinic
Drug Center
Other

レポート目次

Table of Contents

1 Traditional Chemotherapy Drugs for Multiple Myeloma Market Overview
1.1 Product Overview and Scope of Traditional Chemotherapy Drugs for Multiple Myeloma
1.2 Classification of Traditional Chemotherapy Drugs for Multiple Myeloma by Types
1.2.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Comparison by Types (2019-2024)
1.2.2 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Types in 2018
1.2.3 Melphalan
1.2.4 Vincristine
1.2.5 Cyclophosphamide
1.2.6 Etoposide
1.2.7 Doxorubicin
1.2.8 Liposome Doxorubicin
1.2.9 Bendamustine
1.2.10 Other
1.3 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market by Application
1.3.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market by Regions
1.4.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.5 Global Market Size of Traditional Chemotherapy Drugs for Multiple Myeloma (2014-2024)
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 Business Overview
2.1.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.2 Celon Laboratories
2.2.1 Business Overview
2.2.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Celon Laboratories Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.3 Natco Pharma
2.3.1 Business Overview
2.3.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Natco Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.4 Emcure Pharmaceuticals
2.4.1 Business Overview
2.4.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Emcure Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.5 GLS Pharma
2.5.1 Business Overview
2.5.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GLS Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.6 Talon Therapeutics
2.6.1 Business Overview
2.6.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Talon Therapeutics Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.7 Shenzhen Main Luck Pharmaceuticals
2.7.1 Business Overview
2.7.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Shenzhen Main Luck Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.8 Cipla
2.8.1 Business Overview
2.8.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Cipla Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.9 ACTIZA
2.9.1 Business Overview
2.9.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 ACTIZA Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.10 Hospira
2.10.1 Business Overview
2.10.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Hospira Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.11 Baxter
2.11.1 Business Overview
2.11.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Baxter Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.12 Roxane
2.12.1 Business Overview
2.12.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Roxane Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.13 Sanofi
2.13.1 Business Overview
2.13.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Sanofi Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.14 CSC Pharmaceuticals
2.14.1 Business Overview
2.14.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 CSC Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.15 LGM Pharma
2.15.1 Business Overview
2.15.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 LGM Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.16 Pfizer
2.16.1 Business Overview
2.16.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Pfizer Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.17 Merck
2.17.1 Business Overview
2.17.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Merck Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.18 Allergan
2.18.1 Business Overview
2.18.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Allergan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.19 Teva
2.19.1 Business Overview
2.19.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Teva Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.20 Mylan
2.20.1 Business Overview
2.20.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Mylan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.21 Qilu Pharmaceutical
2.21.1 Business Overview
2.2.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Qilu Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.22 Sun Pharmaceuticals
2.22.1 Business Overview
2.22.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Sun Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.23 Cadila Pharmaceuticals
2.23.1 Business Overview
2.23.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Cadila Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.24 Simcere Pharmaceutical
2.24.1 Business Overview
2.24.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Simcere Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.25 Get Well Pharmaceutical
2.25.1 Business Overview
2.25.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Get Well Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
3 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Competition, by Players
3.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Traditional Chemotherapy Drugs for Multiple Myeloma Players Market Share
3.2.2 Top 10 Traditional Chemotherapy Drugs for Multiple Myeloma Players Market Share
3.3 Market Competition Trend
4 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size by Regions
4.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Market Share by Regions
4.2 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.3 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.5 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
5.1 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
5.2 USA Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.3 Canada Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.4 Mexico Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
6.1 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
6.2 Germany Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.3 UK Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.4 France Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.5 Russia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.6 Italy Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
7.1 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
7.2 China Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.3 Japan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.4 Korea Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.5 India Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
8.1 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
8.2 Brazil Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.3 Argentina Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.4 Colombia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Traditional Chemotherapy Drugs for Multiple Myeloma by Countries
9.1 Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
9.2 Saudi Arabia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.3 UAE Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.4 Egypt Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.5 Nigeria Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.6 South Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
10 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Segment by Type
10.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Market Share by Type (2014-2019)
10.2 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Forecast by Type (2019-2024)
10.3 Melphalan Revenue Growth Rate (2014-2024)
10.4 Vincristine Revenue Growth Rate (2014-2024)
10.5 Cyclophosphamide Revenue Growth Rate (2014-2024)
10.6 Etoposide Revenue Growth Rate (2014-2024)
10.7 Doxorubicin Revenue Growth Rate (2014-2024)
10.8 Liposome Doxorubicin Revenue Growth Rate (2014-2024)
10.9 Bendamustine Revenue Growth Rate (2014-2024)
10.10 Other Revenue Growth Rate (2014-2024)
11 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Segment by Application
11.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Application (2014-2019)
11.2 Traditional Chemotherapy Drugs for Multiple Myeloma Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Clinic Revenue Growth (2014-2019)
11.5 Drug Center Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.2 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Forecast by Regions (2019-2024)
12.3 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.4 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.6 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source

List of Tables and Figures

Figure Traditional Chemotherapy Drugs for Multiple Myeloma Picture
Table Product Specifications of Traditional Chemotherapy Drugs for Multiple Myeloma
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma and Revenue (Million USD) Market Split by Product Type
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Types in 2018
Figure Melphalan Picture
Figure Vincristine Picture
Figure Cyclophosphamide Picture
Figure Etoposide Picture
Figure Doxorubicin Picture
Figure Liposome Doxorubicin Picture
Figure Bendamustine Picture
Figure Other Picture
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) by Application (2014-2024)
Figure Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Applications in 2018
Figure Hospital Picture
Figure Clinic Picture
Figure Drug Center Picture
Figure Other Picture
Table Global Market Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table GlaxoSmithKline Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table GlaxoSmithKline Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Celon Laboratories Basic Information, Manufacturing Base and Competitors
Table Celon Laboratories Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Celon Laboratories Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Natco Pharma Basic Information, Manufacturing Base and Competitors
Table Natco Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Natco Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Emcure Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Emcure Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Emcure Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table GLS Pharma Basic Information, Manufacturing Base and Competitors
Table GLS Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table GLS Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Talon Therapeutics Basic Information, Manufacturing Base and Competitors
Table Talon Therapeutics Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Talon Therapeutics Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Shenzhen Main Luck Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Shenzhen Main Luck Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Shenzhen Main Luck Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Cipla Basic Information, Manufacturing Base and Competitors
Table Cipla Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Cipla Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table ACTIZA Basic Information, Manufacturing Base and Competitors
Table ACTIZA Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table ACTIZA Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Hospira Basic Information, Manufacturing Base and Competitors
Table Hospira Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Hospira Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Baxter Basic Information, Manufacturing Base and Competitors
Table Baxter Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Baxter Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Roxane Basic Information, Manufacturing Base and Competitors
Table Roxane Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Roxane Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Sanofi Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table CSC Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table CSC Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table CSC Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table LGM Pharma Basic Information, Manufacturing Base and Competitors
Table LGM Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table LGM Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Pfizer Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Merck Basic Information, Manufacturing Base and Competitors
Table Merck Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Merck Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Allergan Basic Information, Manufacturing Base and Competitors
Table Allergan Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Allergan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Teva Basic Information, Manufacturing Base and Competitors
Table Teva Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Teva Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Mylan Basic Information, Manufacturing Base and Competitors
Table Mylan Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Mylan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Qilu Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Qilu Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Sun Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Sun Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Sun Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Cadila Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Cadila Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Cadila Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Simcere Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Simcere Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Simcere Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Get Well Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Get Well Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
Table Get Well Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) by Players (2014-2019)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Players (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Players in 2017
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Players in 2018
Figure Global Top 5 Players Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share in 2018
Figure Global Top 10 Players Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share in 2018
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) by Regions (2014-2019)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Regions (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Regions (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Regions in 2018
Figure North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
Table North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure USA Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Canada Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Mexico Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Figure Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Germany Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure UK Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure France Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Russia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Italy Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure China Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Japan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Korea Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure India Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
Table South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Brazil Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Argentina Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Colombia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Saudi Arabia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure UAE Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Egypt Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Nigeria Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure South Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) by Type (2014-2019)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Type (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Type (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Type in 2018
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Forecast by Type (2019-2024)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Share Forecast by Type (2019-2024)
Figure Global Melphalan Revenue Growth Rate (2014-2019)
Figure Global Vincristine Revenue Growth Rate (2014-2019)
Figure Global Cyclophosphamide Revenue Growth Rate (2014-2019)
Figure Global Etoposide Revenue Growth Rate (2014-2019)
Figure Global Doxorubicin Revenue Growth Rate (2014-2019)
Figure Global Liposome Doxorubicin Revenue Growth Rate (2014-2019)
Figure Global Bendamustine Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Application (2014-2019)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Application (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Application (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Share by Application in 2018
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Forecast by Application (2019-2024)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Share Forecast by Application (2019-2024)
Figure Global Hospital Revenue Growth Rate (2014-2019)
Figure Global Clinic Revenue Growth Rate (2014-2019)
Figure Global Drug Center Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)

Global Targeted Drugs for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C5677 2019年8月 136Pages
本調査レポートは、多発性骨髄腫用標的治療薬の世界市場について調べ、まとめました。種類別セグメントは、免疫調節剤、プロテアソーム阻害剤、ヒストンデアセチラーゼ阻害剤（HDACI）、モノクローナル抗体、その他等、用途別セグメントは、異種LAN、LAN及びWAN相互接続、WAN及びWAN相互接続、LAN及...

多発性骨髄腫プロテアソーム阻害薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Proteasome Inhibitors for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C4758 2019年8月 109Pages
本調査レポートは、多発性骨髄腫プロテアソーム阻害薬の世界市場について調べ、まとめました。種類別セグメントは、ボルテゾミブ、カルフィルゾミブ、イキサゾミブ、その他等、用途別セグメントは、ものづくり、ヘルスケア、輸送、情報通信、エネルギー・ユーティリティ、その他等に区分しました。多発性骨髄腫プロテアソー...

世界の多発性骨髄腫の治療市場：市場規模・現状・予測

Global Multiple Myeloma Treatment Market Size, Status and Forecast 2019-2025
QYR9N7601 2019年6月14日 94Pages
当資料は、多発性骨髄腫の治療のグローバル市場について調査・分析したレポートで、種類別（プロテアソーム阻害剤、免疫調節剤（IMiD）、ヒストンデアセチラーゼ（HDAC）阻害剤、免疫療法、細胞毒性化学療法）、用途別（病院、診療所、がん治療とリハビリセンター）、主要地域別（アメリカ、ヨーロッパ、中国、日本...

多発性骨髄腫に対するモノクローナル抗体の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Monoclonal Antibody for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C3858 2019年8月 119Pages
本調査レポートは、多発性骨髄腫に対するモノクローナル抗体の世界市場について調べ、まとめました。種類別セグメントは、エロツズマブ、ダラツムマブ、シルツキシマブ、ダセツズマブ、リツキシマブ、その他等、用途別セグメントは、自己免疫疾患、腫瘍学、代謝性疾患、眼科学、循環器疾患、感染症、神経疾患、呼吸器疾患、...

多発性骨髄腫用免疫調節剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Immunomodulator for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C2942 2019年8月 123Pages
本調査レポートは、多発性骨髄腫用免疫調節剤の世界市場について調べ、まとめました。種類別セグメントは、サリドマイド、レナリドマイド、ポマリドマイド、その他等、用途別セグメントは、個人用、商業用、工業用等に区分しました。多発性骨髄腫用免疫調節剤の世界市場概観、企業動向、企業別多発性骨髄腫用免疫調節剤シェ...

骨がん治療薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Bone Cancer Drugs Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C0880 2019年7月 120Pages
本調査レポートは、骨がん治療薬の世界市場について調べ、まとめました。種類別セグメントは、化学療法、標的療法等、用途別セグメントは、等に区分しました。骨がん治療薬の世界市場概観、企業動向、企業別骨がん治療薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、ア...

化学療法薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Chemotherapy Drug Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C1196 2019年7月 120Pages
本調査レポートは、化学療法薬の世界市場について調べ、まとめました。種類別セグメントは、代謝拮抗物質、植物アルカロイド、アルキル化剤、抗腫瘍抗生物質等、用途別セグメントは、等に区分しました。化学療法薬の世界市場概観、企業動向、企業別化学療法薬シェア、市場規模推移、市場規模予測（2019年-2024年）...

化学療法誘発性好中球減少症治療の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Chemotherapy-Induced Neutropenia Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C1198 2019年7月 118Pages
本調査レポートは、化学療法誘発性好中球減少症治療の世界市場について調べ、まとめました。種類別セグメントは、抗生物質療法、コロニー刺激因子療法、顆粒球輸血、脾臓摘出術、その他等、用途別セグメントは、等に区分しました。化学療法誘発性好中球減少症治療の世界市場概観、企業動向、企業別化学療法誘発性好中球減少...

マルチリモートタワーの世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Multiple Remote Tower Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C3903 2019年7月 123Pages
本調査レポートは、マルチリモートタワーの世界市場について調べ、まとめました。種類別セグメントは、空港設備、リモートタワーモジュール、ネットワークソリューション等、用途別セグメントは、等に区分しました。マルチリモートタワーの世界市場概観、企業動向、企業別マルチリモートタワーシェア、市場規模推移、市場規...

化学療法輸液セットの世界市場予測 2019年：メーカー別、地域別、種類・用途別（～2024）

Global Chemotherapy Infusion Set Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
B-GIR08C1197 2019年8月 121Pages
本調査レポートは、化学療法輸液セットの世界市場について調べ、まとめました。種類別セグメントは、フィルター付き、フィルターなし等、用途別セグメントは、病院、医療機器販売店、その他等に区分しました。化学療法輸液セットの世界市場概観、企業動向、企業別化学療法輸液セットシェア、市場規模推移、市場規模予測（2...

多発性骨髄腫用標的治療薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drugs for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially…
世界の多発性骨髄腫の治療市場：市場規模・現状・予測 Multiple myeloma is a cancer formed due to malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Plasma cells helps to fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to acc…
多発性骨髄腫プロテアソーム阻害薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Proteasome Inhibitors for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, esp…
多発性骨髄腫に対するモノクローナル抗体の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Monoclonal Antibody for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, espec…
多発性骨髄腫用免疫調節剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Immunomodulator for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especiall…